ImmunoGen, Inc. is a biotechnology innovator, harnessing the potential of antibody-drug conjugates (ADCs) to revolutionize cancer treatment. With a focus on oncology, the company combines the precision of antibodies with the effectiveness of cytotoxic drugs, aiming to target cancer cells while sparing healthy tissues.
Founded in 1981, ImmunoGen has established a solid presence within the biotechnology and health care sectors. Its mission aligns with pressing global needs in domains like immunology, oncology, and neuroscience, reflected in its slogan: "Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, aesthetics, and other areas of unmet need." Despite not having a specific headquarters listed, its influence is undeniably vast.
As of November 2023, ImmunoGen drew significant attention with an acquisition investment from AbbVie. This strategic move highlights the company's strong potential and the market's confidence in its innovative capabilities.
ImmunoBiochem Corporation
